Experimental approaches to genetic studies of complex traits evolve with technological advances. How do discoveries using different approaches advance our knowledge of the genetic architecture underlying complex diseases/traits? Do most of the findings of newer techniques, such as genome-wide association study (GWAS), provide more information than older ones, for example, genome-wide linkage study? In this review, we address these issues by developing a nicotine dependence (ND) genetic susceptibility map based on the results obtained by the approaches commonly used in recent years, namely, genome-wide linkage, candidate gene association, GWAS and targeted sequencing. Converging and diverging results from these empirical approaches have elucidated a preliminary genetic architecture of this intractable psychiatric disorder and yielded new hypotheses on ND etiology. The insights we obtained by putting together results from diverse approaches can be applied to other complex diseases/ traits. In sum, developing a genetic susceptibility map and keeping it updated are effective ways to keep track of what we know about a disease/trait and what the next steps may be with new approaches.
INTRODUCTION
Along with technological advances, experimental approaches for the genetic study of complex diseases/traits have evolved from genome-wide linkage study to candidate gene association study and from genome-wide association study (GWAS) to targeted sequencing. With improvements in accuracy, coverage and cost, whole-exome and whole-genome sequencing studies seem to be the next mainstream approaches. Are the discoveries from all of these approaches consistent? Should we focus on results obtained with newer approaches; for example, GWAS, and abandon findings from older ones, such as genome-wide linkage study, in the literature sea? How can we make the findings guide our understanding of the genetic architecture of the disease/trait in question? In this review, we use nicotine dependence (ND) as an example to investigate these issues.
Tobacco smoking poses significant threats to public health and kills 46 million people annually worldwide, making it one of the three leading components of the global disease burden in 2010. 1 Despite 50 years of prevention efforts, smoking remains the greatest cause of preventable diseases and deaths; each year, nearly 500 000 Americans die prematurely from smoking, and 416 million Americans suffer from a disease caused by smoking. Although today's users smoke fewer cigarettes than those 50 years ago, they are at higher risk of developing adenocarcinoma, possibly because of ventilated filters and greater amounts of tobacco-specific nitrosamines in cigarettes. 2 Since the 1980s, a broad scientific consensus has been established that ND is the primary factor maintaining smoking behavior. 3 Along with others, we have shown strong evidence for the involvement of genetics in ND, with an average heritability of 0.56. 4, 5 In the past dozen years, considerable efforts have been exerted to identify the genetic factors underlying ND. However, only three widely accepted 'successes;' that is, the neuronal nicotinic acetylcholine receptor gene clusters on chromosomes 15 (CHRNA5/A3/B4) [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] and 8 (CHRNB3/A6) 13, 15, 18, [21] [22] [23] [24] [25] and the genes encoding nicotine-metabolizing enzymes on chromosome 19 (CYP2A6/A7), 16, 18, [26] [27] [28] meet community standards for significance and replication. 29 These few triumphs stand in contrast to the limited heritability they explain; for example, the most significant synonymous single-nucleotide polymorphism (SNP) rs1051730 (P = 2.75 × 10 − 73 ) in CHRNA3 accounted for only 0.5% of the variance in cigarettes smoked per day (CPD) in a meta-analysis of 73 853 subjects. 16 Researchers have suggested that 'missing heritability' is merely hidden and that additional loci can be discovered in GWAS with larger samples, 30, 31 not to mention that the largest ND GWAS to date included 143 023 subjects, 16 and many relevant genetic loci have been revealed with other experimental approaches, such as genome-wide linkage, hypothesis-driven candidate gene association and targeted sequencing. Despite the fact that many non-GWAS findings have an uncertain yield or failed to be replicated, sorting out genetic loci with evidence from multiple approaches is not only essential but also more cost effective than pursuing a formidable sample size for GWAS.
In this communication, we first review the literature on genetics studies for all smoking-related phenotypes using different approaches by highlighting the converging results from different approaches and then offer new hypotheses that have emerged across the allelic spectrum, including common and rare variants.
These findings provide insights into the preliminary genetic architecture of ND, data that are essential for guiding future research. Crucially, we show that developing a genetic susceptibility map with data from various approaches is an effective means of knowledge integration, research progress evaluation and research direction forecast.
GENOME-WIDE LINKAGE STUDIES
For many years, linkage analysis was the primary approach for the genetic mapping of both Mendelian and complex traits with familial aggregation. 32, 33 This method was largely supplanted by the wide adoption of GWAS in the middle 2000s. In 2008, we published a comprehensive review of 420 published genomewide linkage studies of smoking behavior and identified 13 regions, located on chromosomes 3-7, 9-11, 17, 20 and 22, suggestively or significantly linked with various ND measurements in at least two independent samples. 34 Since then, only one genome-wide linkage study has been reported, by Hardin et al., 35 finding a linked spot in the same region as in their previous analysis (6q26) using the same sample but a different phenotype. 36 In addition, Han et al. 37 conducted a meta-analysis of 15 genome-wide linkage scans of smoking behavior and identified two suggestive (5q33.1-5q35.2 and 17q24. 3-q25 . 3 ) and one significant (20q13.12-q13.32) linkage regions. In fact, the regions on chromosomes 5 and 20 expand two of the regions reported in our 2008 review. The region on chromosome 17 reported by Han et al. 37 verified one of the regions detected in only one sample before 2008, which makes it a newly nominated linkage peak (Table 1) . 34 Please refer to Li 34 and Table 1 for detailed information on the 14 nominated linkage regions. Figure 1 also shows updated linkage results after incorporating the findings reported after 2008 by Han et al. 37 
HYPOTHESIS-DRIVEN CANDIDATE GENE ASSOCIATION STUDIES
Candidate gene association studies usually have moderate sample sizes and are much cheaper than GWAS, where the genes examined are selected according to the linkage/GWAS study results or biological hypotheses. However, because of population heterogeneity and liberal statistical thresholds (compared with GWAS) that often are applied, hypothesis-driven candidate gene association studies generally are considered to have an uncertain yield. 38 On the other hand, the abundant results obtained using this approach provide greater depth of exploration of potential targets and offer valuable replication for other unbiased approaches; for example, genome-wide linkage study and GWAS.
To eliminate concerns about potential false-positive results, especially for studies reported in earlier years, we focused primarily on the genes showing significance in at least two independent studies with a sample size of ≥ 1000 or within (or close to) nominated linkage regions or overlapping with GWAS results but with a sample size of ≥ 500 based on the statistical thresholds set by each study. As the reported sex-average recombination rate is 1.30 ± 0.80 cM megabase pairs (Mbp) -1 , 39 in this report, we defined candidate genes within 2 Mbp of any linkage region as 'within' and 2-5 Mbp as 'close to.' The sample size requirement was determined with the following parameters: two-tailed α = 0.05, population risk = 0.30, minor allele frequencies = 0.20 and genotypic relative risk = 1.3 with an approximate odds ratio (OR) of 1.5 or 0.7, which is similar to the statistics usually found in candidate gene association studies. For a statistical power of 0.80 (β = 0.20) using the allelic test, the minimum sample size for a case-control study is 1062, with equal numbers of cases and controls. Of the reported 201 candidate gene association studies, only 88 have had a sample size of 1000 or more. Considering the detected power of 0.54 for a sample size of 500 under the dominant genetic model, we also included genes implicated in studies with 500-1000 subjects if the genes were located in a nominated linkage peak 34 or overlapped with GWAS signals. In total, 34 genetic loci with 43 genes met the criteria ( Table 2 and Figure 1 ), which were assigned to the following four groups. For details on those studies that failed to pass the thresholds but show positive associations, please see Supplementary Table 1 .
Neurotransmitter system genes Dopaminergic system. The dopaminergic system has long been acknowledged to have a critical role in nicotine addiction. 40 The most studied gene in this system is DRD2, located on chromosome 11q23.2 within a modest linkage peak. 41 The intriguing polymorphism Taq1A is located in ANKK1 near DRD2, leading to an amino-acid change in ANKK1. 42 Several other variants and haplotypes in regions adjacent to DRD2, within TTC12 and ANKK1, or downstream of DRD2 have been associated with smokingrelated phenotypes. 13, [43] [44] [45] [46] [47] Besides DRD2, a modest number of studies have shown significant associations between ND traits and other dopamine receptor genes, such as DRD1 (ref. 48 ) and DRD4, [49] [50] [51] and genes involved in dopamine metabolism, including dopamine β-hydroxylase (DBH), 13, 52, 53 DOPA decarboxylase (DDC) 54, 55 and catechol-O-methyl transferase (COMT). [56] [57] [58] [59] [60] [61] All of these genes are within or close to the nominated linkage peaks 34 except for DBH and DDC, which have received support from GWAS results 16 and as ND-associated genes from two independent studies with sample sizes ≥ 1000. 13, [50] [51] [52] [53] Huang et al. 62 implicated DRD3 as a susceptibility gene for ND, but this result has not yet been replicated. Meanwhile, Stapleton et al. 63 showed a significant association of a dopamine transporter gene (SLC6A3) with smoking cessation in a meta-analysis of 2155 subjects (80% of European ancestry), although this finding received only weak support from another study on age at smoking initiation in 668 Asians. 64 This gene group includes two others, protein phosphatase 1 regulatory subunit 1B (PPP1R1B) and μ-opioid receptor (OPRM1), on the basis of their functional connections with dopamine in studies of other addictive substances. PPP1R1B, also known as dopamine-and cAMPregulated neuronal phosphatase (DARPP-32), encodes a key phosphoprotein involved in the regulation of several signaling cascades for dopaminoceptive neurons in several areas of the brain, which also is required for the biochemical effects of cocaine. 65 Activation of OPRM1 in the ventral tegmental area suppresses the activity of inhibitory GABAergic interneurons, resulting in disinhibition of dopamine neurons and dopamine release from terminals in the ventral striatum. 66 OPRM1 A118G variation is a genetic determinant of the striatal dopamine response to alcohol in men, 66 with a preliminary study of tobacco smoking confirming this result. 67 Although we believe in the importance of the above-mentioned genes in ND based on rigorous scientific evidence, the inconsistent results are worth further examination. [68] [69] [70] [71] [72] GABAergic and serotonergic systems. For the GABAergic system, variants in the GABA B receptor subunit 2 (GABBR2), 73 GABA A receptor-associated protein (GABARAP), 74 and GABA A receptor subunits alpha-2 (GABRA2) and -4 (GABRA4) 13, 75, 76 were significantly associated with different ND phenotypes. Cui et al. 77 reviewed the significance of the GABAergic system in ND and alcohol dependence. In addition, the serotonergic system is implicated in susceptibility to ND because nicotine increases serotonin release in the brain, and symptoms of nicotine withdrawal are associated with diminished serotonergic neurotransmission. 78 Genes encoding serotonin receptor 3A, ionotropic (HTR3A), 79 5A, G protein-coupled (HTR5A) 13 and serotonin transporter (SLC6A4) [80] [81] [82] showed significant association with smoking-related behaviors. All of these seven genes of the GABAergic and serotonergic systems are within or close to the nominated linkage peaks, 34 which strengthens the validity of the identified associations, although two studies reported
Linkage region
Candidate gene association study GWAS Next generation sequencing study Figure 1 . The nicotine dependence (ND) genetic susceptibility map with nominated linkage peaks and candidate genes, as suggested by genome-wide linkage, hypothesis-driven candidate gene association (CAS), genome-wide association (GWAS) and targeted sequencing (nextgeneration sequencing; NGS) studies. Linkage peaks are marked in light gray; CAS, GWAS and NGS results are presented as gene names at the outer, middle and inner rings, respectively. negative results for association between serotonin transporter gene (SLC6A4) and smoking behavior. 83, 84 Another gene worth mentioning for this group is serotonin receptor 2A, G proteincoupled (HTR2A), which is within a modest linkage peak (13q14) suggested by Li et al. 85 and was significantly associated with smoking status in a Brazilian sample of 625 subjects. 86 Replication in larger samples is needed to confirm association of this gene with ND.
Glutamatergic system and related genes. Two glutamate receptors, ionotropic, NMDA 3A (GRIN3A), within the nominated linkage peak on 9q21.33-q33, 34 and NMDA 2B (GRIN2B), suggested by one GWAS 87 and close to a modest linkage peak on 12p13. 31-13.32, 88 were significantly associated with scores on the Fagerström test for ND (FTND). 89, 90 More genes in the glutamatergic system, such as GRIN2A, GRIK2, GRM8 and SLC1A2, showed suggestive association with smoking behavior in the GWAS reported by Vink et al. 87 but without significant replication in candidate gene association studies. Accumulating evidence suggests that blockade of glutamatergic transmission attenuates the positive reinforcing and incentive motivational aspects of nicotine, inhibits the reward-enhancing and conditioned rewarding effects of nicotine, and blocks nicotine-seeking behavior. 91 More attention may be paid to this neurotransmitter system in the future.
In the catch-all part, after showing suggestive association in the first ND GWAS, 92 neurexin 1 (NRXN1) association has been replicated in two independent studies with 42000 subjects of three ancestries: African, Asian and European. 93, 94 Although neurexin 3 (NRXN3) also showed a significant association with the risk of being a smoker, 95 this finding has not been verified in any other ND samples, and NRXN3 is not within any detected linkage peak. 34 Neurexins are cell adhesion molecules that have a key role in synapse formation and maintenance and have been implicated in polysubstance addiction. 96 nAChR subunit and other cholinergic system genes As nicotinic receptor (nAChR) subunit gene clusters on chromosomes 15 (CHRNA5/A3/B4) and 8 (CHRNB3/A6) are major discoveries from ND GWAS, their candidate association results will be discussed together with the GWAS results. Significant association of variants in two other subunit genes (CHRNA4 and CHRNB1) did not approach genome-wide significance (GWS; P o5 × 10 − 8 ), but they are both close to nominated linkage peaks. 34 Association of CHRNA4 with ND, close to the nominated linkage peak on 20q13. 12-13.32, 34 has been demonstrated in five independent studies (Table 2) . 90, [97] [98] [99] [100] Variants within CHRNB1, located close to the nominated linkage peak on 17p13.1-q22, 34 are significantly associated with FTND and CPD scores. 90, 101 Two other genes encoding nAChR subunits, CHRNB2 and CHRNA2, although associated with ND-related phenotypes in two studies, 102, 103 are not within any detected linkage peaks and have no replication studies reported that are of the required sample size. Thus, these two genes are considered to have only weak evidence of involvement in ND and therefore are not included in Figure 1 and Table 2 . Besides nAChR subunit genes, two cholinergic receptors, muscarinic 1 (CHRM1) and 2 (CHRM2), were found to be significantly associated with CPD and FTND, respectively. 90, 101 They are within nominated linkage peaks as well. 34 However, because of the inadequacy of knowledge of their biological functions, they have been less investigated.
Nicotine metabolism genes
Of the nicotine metabolism genes, those encoding nicotinemetabolizing enzymes (CYP2A6 and CYP2B6) have been most investigated. 104 Six studies have provided consistent evidence that variants leading to reduced or absent CYP2A6 activity are associated with various smoking-related phenotypes, including is presented, and only the most significant P-value is shown for each variant if multiple phenotypes were tested in different ethnic/gender groups. Corresponding ethnic/gender group or special analysis methods, such as meta-analysis and interaction, for each P-value are noted in parentheses right after. Variants composing the most significant haplotype are given if none of the single variants tested was statistically significant. Corresponding effect sizes are provided whenever available.
The general term 'smoking cessation' was used in the 'Phenotype' column for ease of summarization, which represents abstinence at different time points for different studies. Variant positions are based on NCBI Build 37/hg19. For loci with multiple genes, symbols of the gene variants are indicated in parentheses following the variant type.
Converging findings on addictions J Yang and MD Li the nicotine metabolite ratio (NMR), 105 time to smoking relapse, 27 exhaled carbon monoxide (CO), 28 initial subjective response to nicotine, 82 FTND 13 and CPD. 106 All six samples consisted of subjects of European descent ( Table 1 ). The negative result of CYP2A6 in the 2004 meta-analytic review contrasts with the findings from more recent studies, which we believe offer stronger statistical evidence. 107 Such significant association of variants in the EGLN2-CYP2A6-CYP2B6 region with ND is corroborated by GWAS results, as discussed in the next section. 18, 26 Mitogen-activated protein kinase signaling pathway and other genes Although space limitations do not permit an exhaustive review, we want to acknowledge studies implicating other genes in ND, including brain-derived neurotrophic factor (BDNF), 108,109 neurotrophic tyrosine kinase, receptor type 2 (NTRK2), 110 arrestin, beta 1 (ARRB1), 111 MAP3K4, 90 SHC3, 112 dynamin 1 (DNM1), 113 taste receptor type 2, member 38 (TAS2R38), 114 amyloid beta precursor proteinbinding, family B, member 1 (APBB1), 115 PTEN 116 and neuregulin 3 (NRG3). 117 It is worth noting that the first five of these genes belong to the mitogen-activated protein kinase signaling pathway, which was identified as significantly enriched in involvement with four drugs subject to abuse, namely, cocaine, alcohol, opioids, and nicotine. 118
GENOME-WIDE ASSOCIATION STUDIES
Although the concept of GWAS was initially proposed in 1996, 119 no GWAS was conducted until 2005. 120 Since then, this technique became the preferred mapping tool for complex diseases/traits. 32 As of October 2015, nine published GWASs and meta-GWASs have yielded 11 genetic loci carrying variants of GWS (P o5 × 10 − 8 ) associated with relevant ND phenotypes in subjects of European, African and East Asian ancestries ( Table 3 and Figure 1 ). However, only three loci were replicated in more than two independent GWASs or meta-GWASs, among which the CHRNA5/A3/B4 gene cluster has the most evidence of significance. Before the GWAS reports, Saccone et al. 13 reported significant association of a 3′-UTR variant (rs578776) in CHRNA3 with dichotomized FTND in smokers in a candidate gene association study examining 348 genes. Then, in the GWAS era, five variants in this region reached GWS in five GWAS and meta-GWAS, 12, [16] [17] [18] [19] among which four (rs1051730, rs16969968, rs64952308 and rs55853698) were found to be significant in Europeans, and one (rs2036527) was significantly associated with CPD in AAs. The SNPs rs1051730, rs16969968 and rs55853698 are close-tagging proxies (all pairwise r 2 40.96), 12 and rs2036527 is correlated with rs1051730. 19 All the r 2 s reported in the main text were extracted from the original studies. Thus, these variants were predicted to either tag or potentially cause the principal risk for high smoking quantity attributable to the 15q25 locus, with approximately one CPD step increase for each risk allele. 12, 16, 19 Although the synonymous SNP rs1051730 (Y188Y) in CHRNA3 showed the strongest association, the nonsynonymous SNP rs16969968 (D398N) in CHRNA5 and rs55853698 in the 5′-UTR of CHRNA5 hold more promise of functional importance. In the European samples, conditional on rs16969968 or rs55853698, residual association was detected at rs588765, tagging high expression of CHRNA5 and rs6495308 within CHRNA3 as showing significant association with CPD unconditionally. Liu et al. 12 discovered better model fitting when conditioning on rs55853698 and rs6495308 compared with rs16969968 and rs588765 using the Bayesian information criteria. Both rs588765 and rs6495308 were reported to be in low linkage disequilibrium (LD) with each other (r 2 = 0.21) and both to be in only modest LD with the principal SNPs (maximum r 2 = 0.47) in subjects of European ancestry. 12 However, in the AA samples, no second association signal was detected in this region after conditioning on rs2036527, suggesting that rs20356527 and correlated SNPs in populations of African ancestry define a single common haplotype. 19 At the same time, the finding of importance of this gene cluster has been replicated by candidate gene association studies in persons of Asian ancestry 8, 11 and different ND phenotype-cotinine concentrations, 9 neural responses, 121 smoking cessation successes, [122] [123] [124] age of initiation 125 and CPD during pregnancy. 126 The two most replicated variants in candidate gene association studies, rs16969968 and rs1051730, are consistent with the GWAS results. Please refer to Table 2 for details.
The three GWS SNPs on chromosome 8p11 in samples of African and European ancestries-rs13280604, rs6474412 and rs1451240-are in perfect LD with each other 18, 25 and also with a variant (rs13277254) suggestively associated with the ND status of smokers in the first ND GWAS. 92 As noted by Rice et al., 25 although the dichotomized FTND appeared to have an equivalent relation with rs1451240 across ethnicities, the relation between this SNP and CPD was much weaker in AAs than in EAs. The other two SNPs were both significantly associated with CPD in Europeans. 18 These associated SNPs are either intergenic or intronic, which may tag causal variation(s) within the LD block that contains CHRNB3 and CHRNA6 or regulate the expression of the two genes directly. Significant association of variants in CHRNB3 and CHRNA6 with ND was confirmed in eight candidate gene association studies with diverse population ancestries and smoking traits ( Table 2) . [21] [22] [23] [24] 106, [127] [128] [129] Cui et al. 21 obtained a close to GWS meta-P-value for an upstream variant of CHRNB3 (rs4736835) in a candidate gene association study of 22 654 subjects with African, European and East Asian ancestries.
The last region detected by more than one GWAS or meta-GWAS is on chromosome 19q13.2 and includes genes such as CYP2A6/A7/B6, EGLN2, RAB4B and NUMBL. Thorgeirsson et al. 18 identified rs4105144 and rs7937 as significantly associated with CPD in European samples. These two SNPs were reported to be in LD with each other (r 2 = 0.32 and D′ = 0.82 in the HapMap CEU samples). Rs4105144 was also in LD with CYP2A6*2 (rs1801272; r 2 = 0.13 and D′ = 1.0 in the HapMap CEU samples), which reduces CYP2A6's enzymatic activity. 18 The SNP identified by the Tobacco and Genetics Consortium 16 (rs3733829) lies between these sites and was reported to show moderate LD with rs4105144 and rs7937. Besides association signals in samples with European ancestry, Kumasaka et al. 26 found a copy number variant (CNV; rs8102683) with a strong effect on CPD (β = − 4.00) in a Japanese population and another significantly associated SNP (rs11878604; β = − 2.69) located 30-kb downstream of the CYP2A6 gene after adjustment of the CNV. Rs8102683 shared a deletion region with other CNVs ranging from the 3′ end of the CYP2A6 gene to the 3′ end of the CYP2A7 gene; however, this common deletion was not significant in a European population. 26 Recently, Loukola et al. 130 conducted the first GWAS on NMR and identified 719 GWS SNPs within this region. Strikingly, the significant CYP2A6 variants explain a large fraction of variance (up to 31%) in NMR in their sample.
All the other signals reported by only one GWAS or meta-GWAS can be found in Table 3 and Figure 1 , among which a missense variant rs6265 in BDNF was significantly associated with smoking initiation and an intergenic variant rs3025343 close to DBH was implicated in smoking cessation. 16 It is worth noting that GWASs without GWS variant identification still render valuable information in determining susceptibility loci for ND. The first ND GWAS, performed by Bierut et al., 92 nominated NRXN1 in the development of ND, which was validated by a subsequent candidate gene association study. 93 By using a network-based genome-wide association approach, Vink et al. 87 discovered susceptibility genes encoding groups of proteins, such as glutamate receptors, proteins involved in tyrosine kinase receptor signaling, transporters and cell adhesion molecules, many of which were confirmed in later candidate gene association studies. 89, 110 Please refer to Supplementary Table 1 for a list of GWASs without GWS results. We used the significance threshold of 5 × 10 8 . The most significant GWAS finding from different studies for any specific variant is given. If numerous tightly mapped markers showed GWS in one study, only the most significant one is provided. Variant positions are based on NCBI Build 37/hg19. For many studies, it was not possible to extract the exact sample size used for each locus, so the sizes above are approximate. 'Effect sizes' refers to beta coefficients for CPD and NMR and ORs for smoking initiation and cessation.
TARGETED SEQUENCING STUDIES
As the 'missing heritability' issue emerged in each field, researchers suspected that much of the missing heritability is attributable to genetic variants that are too rare to be detected by GWAS but may have relatively large effects on risk and thus are important to study using next-generation sequencing technologies. 131 Both population genetic theories and empirical studies of several complex traits suggest that rare alleles are enriched for functional and deleterious effects and thus are disproportionately represented among disease alleles. 132 For the field of ND genetics, rare variant investigation started with the nAChR subunit genes, which not only are biologically important but also have yielded the most replicable results in both GWASs and candidate gene association studies, as presented above. Wessel et al. 133 first examined the contribution of common and rare variants in 11 nAChR genes to FTND in 448 EA smokers, which revealed significant effects of common and rare variants combined in CHRNA5 and CHRNB2, as well as of rare variants only in CHRNA4. Xie et al. 134 followed up on the CHRNA4 finding by sequencing exon 5, where most of the nonsynonymous rare variants were detected, in 1000 ND cases and 1000 non-ND controls with equal numbers of EAs and AAs. They discovered that functional rare variants within CHRNA4 may reduce ND risk. Also, Haller et al. 135 detected protective effects of missense rare variants at conserved residues in CHRNB4. They examined in vitro the functional effects of the three major association signal contributors (that is, T375I and T91I in CHRNB4 and R37H in CHRNA3), finding that the minor alleles of the studied SNPs increased the cellular response to nicotine. The two rare variants in CHRNB4 were confirmed to augment nicotine-mediated α3β4 nAChR currents in hippocampal neurons, as did a third variant, D447X, in the report of Slimak et al. 136 The fourth SNP they analyzed, R348C, reduced nicotine currents. They also observed that habenular expression of the β4 gain-of-function allele T374I resulted in strong aversion to nicotine in mice, whereas transduction of the β4 loss-of-function allele R348C failed to induce nicotine aversion. Later, Doyle et al. 137 reported an interesting rare variant in CHRNA5 that could result in nonsensemediated decay of aberrant transcripts in 250 AA heavy smokers. And recently, Yang et al. 138 performed a targeted sequencing study with the goal of determining both the individual and the cumulative effects of rare and common variants in 30 candidate genes implicated in ND. Rare variants in NRXN1, CHRNA9, CHRNA2, NTRK2, GABBR2, GRIN3A, DNM1, NRXN2, NRXN3 and ARRB2 were found to be significantly associated with smoking status in 3088 AA samples, and a significant excess of rare variants exclusive to EA smokers was observed in NRXN1, CHRNA9, TAS2R38, GRIN3A, DBH, ANKK1/DRD2, NRXN3 and CDH13. The 18 genetic loci implicated in targeted sequencing studies are marked in Figure 1 .
IMPLICATIONS
According to our list, 242 candidate gene association, 22 genomewide linkages, 18 GWAS and 5 targeted sequencing, making a total of 287 studies, have been conducted in the ND genetics field. The numbers for genome-wide linkage and candidate gene association studies before 2004 are based on Li 34 and Munafò et al., 139 respectively. As a summary and refining of the 286 ND genetic studies, we developed an ND genetic susceptibility map with 14 linkage regions and 47 unique loci of 60 susceptibility genes (Figure 1) .
Both genome-wide linkage and GWAS are considered 'unbiased' exploratory approaches. By comparing their results, we found that only two GWS signals are within the nominated linkage peaks, which are LOC100188947 and BDNF. 16, 34 The other nine loci, including the three most replicable ones, are all outside of the linkage peaks, and the rest of the 12 linkage regions do not contain any GWS signal (Tables 1 and 2 ). This discrepancy may reflect not only the different natures of the two genome-wide approaches but also different ND measures used among those studies. Genome-wide linkage studies usually investigate sparse microsatellites segregated with the trait of interest in different families, whereas GWAS takes advantage of dense common variants and thousands of unrelated individuals. As a result of the distinct characteristics of family and case-control samples and known locus heterogeneity for ND, we may not expect same sets of susceptibility alleles to be detected by both approaches. The relatively large nominated linkage regions tagged by microsatellites may implicate common or rare variants or both within the region of interest, on the other hand, it is generally believed that only common variants can be detected by GWAS. Moreover, even if a linkage region is driven by common variants, we may still not be able to locate them in GWAS because of the stringent P-values applied for defining significance in GWAS. The presence of GWAS signals outside linkage peaks may also result from the lack of power for linkage studies to detect weak genetic effects exhibited by the loci involved in complex diseases compared with association studies. 119 As one can see, these unbiased approaches are powerful in marking areas in the genome; nevertheless, the areas they indicate are often large and may not be complete. In this case, hypothesis-driven studies are useful and necessary tools not only to scrutinize marked areas, but also to explore promising false-negative results and biologically plausible targets.
Both candidate gene association and targeted sequencing studies serve this purpose. Candidate gene association studies replicated and extended 5 of the 11 GWAS results; that is, CHRNB3/ A6, DBH, BDNF, CHRNA5/A3/B4 and EGLN2/CYP2A6/B6. For the other 29 non-GWS candidate genetic loci, 20 and 7 were selected from within and close to linkage peaks, respectively, the exceptions being NRXN1 and DDC (Table 2) , which reminds us of the importance of examining suggestive results in GWAS, 92 the other two examples being GRIN2B and NTRK2, 87 and biologically plausible genes separately. Although we have localized candidate genes within most of the nominated linkage regions, four linkage peaks, on chromosomes 3q26-q27, 5q11.2-q14, 9p21-p24.1 and 17q24.3-q25.3, are still empty, suggesting there are novel susceptibility genes to be discovered in the future. Overlaps and distinctions from the two unbiased approaches and the significant number of loci reproduced or proposed in candidate gene studies suggest that we have many more study targets with good statistical evidence besides the three most replicable GWAS loci. The fourth 'immature' approach is also hypothesis driven and has verified the importance of rare variants in ND genetics. [133] [134] [135] 138 Besides the demonstrated aggregate effects of rare variants in 12 genetic loci implicated in previous studies, biological candidates showing equivocal or no association beforehand were found to be significantly associated with ND-related phenotypes, such as CHRNB2, CHRNA9, CHRNA2, NRXN2, NRXN3 and CDH13, among which CHRNA9 and NRXN2 are within linkage regions. 34, 138 Thus, we believe whole-exome and whole-genome sequencing studies focusing on rare variants, as the third unbiased experimental approach, will reveal new susceptibility genes/variants and further dissect the existing targets.
It is worth noting that to establish a replication of a genotypephenotype association, every effort should be made to analyze phenotypes comparable to those reported in the original study. 29 However, the ND genetics studies mentioned above involved a plethora of smoking-related phenotypes. Generally speaking, they can be classified into the following groups: (1) categorical variables along smoking trajectories; for example, smoking initiation, status and cessation; (2) ND assessed using DSM-IV or FTND; (3) smoking quantity such as CPD; and (4) endophenotypes such as NMR, cotinine and CO concentrations, or functional imaging results. At least two of the four phenotype groups have Converging findings on addictions been used in genome-wide linkage studies (Table 1) , 34 candidate gene association studies ( Table 2) and GWASs ( Table 3 ). As a result of the sample source and size requirement differences, DSM-or FTND-ascertained ND definitions were commonly used in linkage studies, whereas CPD was more often applied in GWAS. For candidate gene association studies, more comprehensive smoking profiles were usually tested for association with positive results from unbiased studies as replication, or more importantly, extension by using different phenotypes (Table 2) , because there is considerable evidence that the various smoking measures are not highly related to one another. 140 Even for measures with relatively high correlation, such as FTND and CPD, the slight change of phenotype from FTND-based ND to CPD would change the results. 25 Therefore, although several loci, such as TTC12-ANKK1-DRD2, CHRNA5/A3/B4 and CYP2A6/B6 showed associations with different phenotypes (Tables 2 and 3) , we should not expect positive associations with one phenotype to be replicated in samples with other phenotypes. It is important to keep in mind that a small change in phenotype may expose previously undiscovered variants, which underlie different biological processes and may have specific roles in distinguishing phenotypes. 25 In addition, gene-gene and gene-environment interactions are two pieces of information missing from the current map because of the small number of reported studies. We expect more results in these two areas will be published with the development of efficient algorithms and become important parts of the susceptibility map. It also is worth noting that half of the 48 ND loci were significantly associated with alcohol-related phenotypes, and 30% were involved in illicit drug dependence (Supplementary Table 2 ), suggesting that the 60 genes on the ND map are good candidates for addiction studies of other drugs as well.
FUTURE DIRECTIONS
Technological advances enable the development of different experimental approaches. A genetic susceptibility map, as put together in this review, contains scientific evidence from diverse approaches and can serve as a draft of the 'parts list' to be updated periodically until complete. 38 We hope such an enumeration will catalyze an array of specific targeted and nuanced scientific studies, as suggested by Sullivan et al.; 38 for example, calculating the heritability explained by the 47 genetic loci, replicating association signals currently inadequately supported, identifying causal variant(s) within each locus through expression data integration and functional characterization, selecting appropriate phenotypic measures of ND, elucidating biological mechanisms between the genotype and ND, exploring gene-gene and gene-environment interactions, understanding the part played by epigenetic modifications, developing and evaluating treatment prediction models, and so forth.
Although the sample size of candidate gene association studies has increased over the years (Supplementary Figure 1A) , genetic power calculation and corresponding sample size ascertainment should always be a top priority before conducting genetic studies. In addition, only 18% and 10% of the 287 studies investigated subjects with African and Asian ancestries, respectively, compared with 69% for European ancestry (Supplementary Figure 1B) . Studying different populations is necessary to understand the genetic causes of ND in various ethnic groups. Concurrently, given the importance of rare variants suggested by targeted sequencing study results, thorough and well-powered genomic evaluations at the lower end of the allelic spectrum are needed. Whole-exome and whole-genome sequencing studies with enough statistical rigor would enable a substantial update of the ND genetic susceptibility map in the near future.
However, it is important to acknowledge that the genetic liability accounted for by each of the 47 loci is probably o 1% of the phenotypic variance, considering their respective effect sizes, which may also explain why they can be identified through one type of unbiased study, but not the other. Anticipating future studies on the predictive power of these loci cumulatively, we are inclined to project that the amount of heritability explained will 
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In vitro gene expression assay rs3003609 (T) Reduced expression 113 11 still be limited, which renders the susceptibility map as only a beginning. Furthermore, functional studies have been conducted for limited genetic variants with certain or uncertain smoking associations (Table 4 ). Nevertheless, the TTC12-ANKK1-DRD2 cluster shows consistent association with smoking-related behaviors (Table 2) , and the function of the most prominent variation in this region, Taq1A, still is largely unknown. 47 On the other hand, we have understood the molecular and neurobehavioral functional consequences of BDNF Met66Val polymorphism (rs6265) for more than a decade, 141 although its association with ND phenotypes is still relatively weak ( Table 2 ). Combining the susceptibility map results with relevant functional annotations will facilitate determination of variations bearing higher translational values. 142 All in all, this map empowers us to sift through existing accomplishments and ponder future research strategies, an approach that may serve as a useful tool for other complex diseases/traits also.
